UDC: 615.03
BBC: 52.81
Georgieva K.S., Pavlova S.I.
Analysis of Recurrent Haemorrhage Against the Background of Taking Warfarin in a Female Patient of the Chuvash Population (a clinical case)
Keywords: pharmacovigilance, safety of pharmacotherapy, Warfarin, the Chuvash, drug interaction, lack of therapeutic effect
In order to prevent thromboembolic complications in atrial fibrillation in patients with prosthetic heart valves, Warfarin still remains a standard drug in real-life clinical practice. However, against the background of Warfarin therapy, haemorrhage is common; in some cases it can be fatal. The reason for this situation lies in a narrow therapeutic range and wide individual dosage variations of this drug. Among the factors determining the effectiveness and safety of Warfarin, modifiable (for example, drug interactions, bad habits) and non-modifiable (age, gender, genetic characteristics) ones are considered important. The authors of the paper analyzed possible causes of haemorrhage and difficulties with Warfarin dose finding and achievement of targets for international normalized ratio in a female patient who was passing treatment at the Budgetary Institution "Republican Cardiological Dispensary" under the Health Ministry of the Chuvash Republic. Patient K. (a female Chuvash, 68 years old), who received Warfarin for valvular atrial fibrillation, was repeatedly hospitalized (April 2023, August 2023) with signs of haemorrhage after self-medicating with non-steroidal anti-inflammatory drugs and Cephalosporin antibiotics. Among other factors predisposing to changes in sensitivity to Warfarin, the following were identified: old age, female gender, increased body mass index. However, the carrier state of polymorphism in CYP2C9 and VKORC1 genes that increase sensitivity to Warfarin were not diagnosed. Additional difficulties in achieving the targets of international normalized ratio could be associated with the replacement of the drug taken to Warfarin from another manufacturer. The analysis of recurrent cases of hypocoagulation and difficulties in achieving the target values of the international normalized ratio against the background of taking Warfarin did not reveal pharmacogenetic risk factors, but was most likely associated with low compliance, undesirable drug interactions and differences in the therapeutic equivalence of Warfarin drugs used. With the help of a regional medical information system, the patient's condition was updated, the data obtained indicate a possible risk of recurrent haemorrhage, which is probably due to a change in the manufacturer of Warfarin.
References
- Leonova M.V. Klinicheskaya ekvivalentnost’ generikov i original’nykh preparatov, primenyaemykh v kardiologii: chto nam izvestno? [Clinical equivalence of generics and original drugs used in cardiology: What do we know?]. Consilium Medicum, 2021, vol. 23, no.12, рр. 920–927.
- Maksimov L., ed., Maksimov M.L., Bontsevich R.A., Burashnikova I.S. Klinicheskaya farmakologiya i ratsional’naya farmakoterapiya dlya praktikuyushchikh vrachei [Clinical pharmacology and rational pharmacotherapy for practitioners]. Kazan, MeDDoK Рubl., 2021, 948 р.
- Martsevich S.Yu., Kutishenko N.P., Dmitrieva N.A., Belolipetskaya V.G. Vybor lekarstvennogo preparata v kardiologii: na chto dolzhen orientirovat’sya prakticheskii vrach? [The choice of a drug in cardiology: what should a practitioner focus on?]. Kardiovaskulyarnaya terapiya i profilaktika, 2004, vol. 3, no. 4, рр. 77–82.
- Meshkovskii A.P. Mesto dzhenerikov v lekarstvennom obespechenii [The place of generics in drug provision]. Farmateka, 2003, no. 3, рр. 103–104.
- Skirdenko Yu.P., Nikolaev N.A. Novye podkhody k individualizirovannomu vyboru peroral’nykh antikoa-gulyantov u bol’nykh fibrillyatsiei predserdii [New approaches to the individualized choice of oral anticoagulants in patients with atrial fibrillation]. Ratsional’naya farmakoterapiya v kardiologii, 2018, vol.14, no. 1, рр. 58–64.
- Sychev D.A., Shuev G.N., Torbenkov E.S., Adriyanova M.A. Personalizirovannaya meditsina: vzglyad kliniche-skogo farmakologa [Personalized medicine: the view of a clinical pharmacologist]. Consilium Medicum, 2017, vol. 19, no. 1, рр. 61–68.
- Sychev D.A., Antonov I.M., Ignat’ev I.V. Antikoagulyantnoe deistvie i bezopasnost’ primeneniya varfa-rina pri ego dozirovanii, osnovannom na rezul’tatakh farmakogeneticheskogo testirovaniya: rezul’taty pervogo rossiiskogo prospektivnogo issledovaniya [Anticoagulant effect and safety of warfarin administration during its dosing based on the results of pharmacological testing: the results of the first Russian prospective study]. Kardiologiya, 2010,no. 5, рр. 42-46.
- Andrade C. Bioequivalence of generic drugs. J Clin Psychiatry, 2015, vol. 76(9), рр. 1130–1132. DOI: 10.4088/JCP.15f10300.
- Caldeira D., David C., Costa J. et al. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother, 2018, vol. 4(2), рр. 111–118. DOI: 10.1093/ehjcvp/pvx028.
- Camm A. ESC Committee for Practice Guidelines.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace, 2010, vol.12(10), рр. 1360– DOI: 10.1093/eurheartj/ehq278.
- Faasse K., Cundy T., Gamble G., Petrie K. The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects. Psychosom Med., 2013, vol. 75(1), рр. 90– DOI: 10.1097/PSY.0b013e3182738826.
- Malik A., Yandrapalli S., Aronow W. et al. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart, 2019, vol. 105(18), рр. 1432–1436. DOI: 10.1136/heartjnl-2019-314767.
About authors
- Georgieva Ksenia S.
- Assistant Lecturer, Department of Pharmacology, Clinical Pharmacology and Biochemistry , Chuvash State University, Russia, Cheboksary (KseniaPharm@yandex.ru; ORCID: https://orcid.org/0000-0002-8632-1408)
- Pavlova Svetlana I.
- Doctor of Medical Sciences, Associate Professor, Head of the Department of Pharmacology, Clinical Pharmacology and Biochemistry, Chuvash State University, Russia, Cheboksary (flavonoid@yandex.ru; ORCID: https://orcid.org/0000-0001-9976-7866)
Article link
Georgieva K.S., Pavlova S.I. Analysis of Recurrent Haemorrhage Against the Background of Taking Warfarin in a Female Patient of the Chuvash Population (a clinical case) [Electronic resource] // Acta medica Eurasica. – 2024. – №3. P. 49-58. – URL: https://acta-medica-eurasica.ru/en/single/2024/3/6/. DOI: 10.47026/2413-4864-2024-3-49-58.